Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Aug 11 · below the Ichimoku cloud · RSI 27 (oversold) · MACD below its signal
| 5.55 | 52-week high | +208.33% |
| 4.15 | Previous month high | +130.56% |
| 2.26 | Previous week high | +25.56% |
| 2.12 | Previous month low | +17.78% |
| 1.93 | R3 (classic) | +7.41% |
| 1.90 | Previous week low | +5.67% |
| 1.89 | R2 (classic) | +4.81% |
| 1.84 | R1 (classic) | +2.41% |
| 1.84 | Previous day high | +2.22% |
| 1.80 | Price now | |
| 1.80 | Pivot | −0.19% |
| 1.75 | S1 (classic) | −2.59% |
| 1.75 | Previous day low | −2.78% |
| 1.71 | S2 (classic) | −5.19% |
| 1.66 | S3 (classic) | −7.59% |
| 1.03 | 52-week low | −42.78% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $2.3M | 0.00% | 772.23K | −13% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PYXS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 26.1 | 1.4 | -0.7 | 16.4 | 5.9 | 67.2 | -12.0 | 22.3 | -28.1 | -22.7 | +56.5% | ||
| 2025 | 0.6 | -24.2 | -17.6 | 12.2 | 10.0 | -9.1 | 1.8 | 14.3 | 73.4 | 60.4 | 45.8 | -77.8 | −26.3% |
| 2024 | 111.7 | 66.9 | -33.0 | 4.5 | -16.0 | -11.5 | 18.4 | -3.3 | -3.2 | -3.0 | -43.5 | -22.4 | −13.3% |
| 2023 | 16.4 | 45.5 | 76.7 | -26.4 | 9.2 | -20.5 | 0.8 | -15.5 | -8.7 | -16.1 | -4.8 | 13.2 | +34.3% |
| 2022 | -13.0 | -36.3 | -33.6 | -39.4 | 0.8 | -3.6 | 11.3 | -2.3 | -23.9 | -5.1 | -22.5 | -7.6 | −87.8% |
| 2021 | -4.3 | -14.1 | −17.8% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 29, 2026 | Dupont JakobDirector | Conversion of Exercise of derivative security at price 1.60 per share. | 35K | $56.00K |
| Jun 29, 2026 | Dupont JakobDirector | Sale at price 3.06 per share. | 35K | $107.10K |
| Mar 23, 2026 | Wadhane JitendraChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 109.5K | — |
| Apr 20, 2025 | Humphrey Rachel W.Director | Sale at price 0.97 - 1.03 per share. | 15.5K | $15.92K |
| Nov 25, 2024 | Connealy Pamela AnnChief Operating Officer | Purchase at price 1.96 - 2.00 per share. | 88.8K | $174.36K |
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Buy / hold / sell counts